Oligodendroglioma - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 132 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Oligodendroglioma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Oligodendroglioma - Pipeline Review, H1 2016', provides an overview of the Oligodendroglioma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oligodendroglioma
- The report reviews pipeline therapeutics for Oligodendroglioma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Oligodendroglioma therapeutics and enlists all their major and minor projects
- The report assesses Oligodendroglioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Oligodendroglioma

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oligodendroglioma Overview 8
Therapeutics Development 9
Pipeline Products for Oligodendroglioma - Overview 9
Pipeline Products for Oligodendroglioma - Comparative Analysis 10
Oligodendroglioma - Therapeutics under Development by Companies 11
Oligodendroglioma - Therapeutics under Investigation by Universities/Institutes 12
Oligodendroglioma - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Oligodendroglioma - Products under Development by Companies 15
Oligodendroglioma - Products under Investigation by Universities/Institutes 16
Oligodendroglioma - Companies Involved in Therapeutics Development 17
Axelar AB 17
Boehringer Ingelheim GmbH 18
Bristol-Myers Squibb Company 19
Cavion LLC 20
Celgene Corporation 21
Celldex Therapeutics, Inc. 22
e-Therapeutics Plc 23
F. Hoffmann-La Roche Ltd. 24
Millennium Pharmaceuticals, Inc. 25
Novartis AG 26
Pfizer Inc. 27
Tocagen Inc. 28
Oligodendroglioma - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
afatinib dimaleate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
alisertib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AXL-1717 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
bevacizumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CC-122 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CDX-1401 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Cellular Immunotherapy for Brain Tumors - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Cellular Immunotherapy for Gliomas - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Cellular Immunotherapy for Oncology - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
dasatinib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
DNX-2401 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ETS-2101 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
flucytosine + TBio-01 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
flucytosine ER + vocimagene amiretrorepvec - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
irinotecan hydrochloride + TBio-02 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
mibefradil dihydrochloride - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
nilotinib - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
p28 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
palbociclib - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
temsirolimus - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Oligodendroglioma - Recent Pipeline Updates 95
Oligodendroglioma - Dormant Projects 130
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 131
Disclaimer 132

List of Tables

Number of Products under Development for Oligodendroglioma, H1 2016 9
Number of Products under Development for Oligodendroglioma - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Oligodendroglioma - Pipeline by Axelar AB, H1 2016 17
Oligodendroglioma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 18
Oligodendroglioma - Pipeline by Bristol-Myers Squibb Company, H1 2016 19
Oligodendroglioma - Pipeline by Cavion LLC, H1 2016 20
Oligodendroglioma - Pipeline by Celgene Corporation, H1 2016 21
Oligodendroglioma - Pipeline by Celldex Therapeutics, Inc., H1 2016 22
Oligodendroglioma - Pipeline by e-Therapeutics Plc, H1 2016 23
Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 24
Oligodendroglioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 25
Oligodendroglioma - Pipeline by Novartis AG, H1 2016 26
Oligodendroglioma - Pipeline by Pfizer Inc., H1 2016 27
Oligodendroglioma - Pipeline by Tocagen Inc., H1 2016 28
Assessment by Monotherapy Products, H1 2016 29
Assessment by Combination Products, H1 2016 30
Number of Products by Stage and Target, H1 2016 32
Number of Products by Stage and Mechanism of Action, H1 2016 34
Number of Products by Stage and Route of Administration, H1 2016 36
Number of Products by Stage and Molecule Type, H1 2016 38
Oligodendroglioma Therapeutics - Recent Pipeline Updates, H1 2016 95
Oligodendroglioma - Dormant Projects, H1 2016 130